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Abstract
Introduction Proteasome inhibition is an attractive approach to
anticancer therapy and may have relevancy in breast cancer
treatment. Natural products, such as dietary flavonoids, have
been suggested as natural proteasome inhibitors with potential
use for cancer prevention and therapeutics. We previously
reported that apigenin, a flavonoid widely distributed in many
fruits and vegetables, can inhibit proteasome activity and can
induce apoptosis in cultured leukemia Jurkat T cells. Whether
apigenin has proteasome-inhibitory activity in the highly
metastatic human breast MDA-MB-231 cells and xenografts,
however, is unknown.
Methods MDA-MB-231 breast cancer cell cultures and
xenografts were treated with apigenin, followed by
measurement of reduced cellular viability/proliferation,
proteasome inhibition, and apoptosis induction. Inhibition of the
proteasome was determined by levels of the proteasomal
chymotrypsin-like activity, by ubiquitinated proteins, and by
accumulation of proteasome target proteins in extracts of the
treated cells or tumors. Apoptotic cell death was measured by
capase-3/caspase-7 activation, poly(ADP-ribose) polymerase
cleavage, and immunohistochemistry for terminal nucleotidyl
transferase-mediated nick end labeling positivity.
Results We report for the first time that apigenin inhibits the
proteasomal chymotrypsin-like activity and induces apoptosis
not only in cultured MDA-MB-231 cells but also in MDA-MB-
231 xenografts. Furthermore, while apigenin has antibreast
tumor activity, no apparent toxicity to the tested animals was
observed.
Conclusion We have shown that apigenin is an effective
proteasome inhibitor in cultured breast cancer cells and in
breast cancer xenografts. Furthermore, apigenin induces
apoptotic cell death in human breast cancer cells and exhibits
anticancer activities in tumors. The results suggest its potential
benefits in breast cancer prevention and treatment.
Introduction
Regular consumption of a variety of polyphenolic compounds
has been associated with reduced cancer risk and with tumor
growth suppression [1]. The polyphenolic flavone apigenin is
widely distributed among fruits and vegetables, and apigenin
has been shown to possess chemopreventive activities in a
number of cancer models including those of lung cancer [2],
skin cancer [3], cervical cancer [4], prostate cancer [5], and
leukemia [6]. The mechanisms by which apigenin imparts its
anticancer effects are varied and may include action through
antiinflammation [7], free radical scavenging [8], and proteas-
ome inhibition [6,9].
The eukaryotic proteasome is a large multicatalytic, multisubu-
nit protease complex possessing at least three distinct activi-
ties, which are associated with three different β subunits,
respectively: chymotrypsin-like activity (with the β5 subunit),
trypsin-like activity (with the β2 subunit), and peptidyl-glutamyl
peptide-hydrolyzing-like (caspase-like) activity (with the β1
subunit) [10]. Inhibition of the chymotrypsin-like activity, but
AMC = 7-amino-4-methylcoumarin; DMSO = dimethylsulfoxide; MTT = 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide; PARP = 
poly(ADP-ribose) polymerase; PBS = phosphate-buffered saline; TUNEL = terminal nucleotidyl transferase-mediated nick end labeling.
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not of the trypsin-like activity, of the proteasome has been
associated with induction of tumor cell apoptosis [11,12]. By
examining a broad range of cell culture models, it has been
found that proteasome inhibitors rapidly induce tumor cell
apoptosis, selectively activate the cell death program in can-
cer or oncogene-transformed cells, but not in normal or
untransformed cells, and are able to trigger apoptotic death in
human cancer cells that are resistant to various anticancer
agents [9,11,13-18].
The most described and best known proteasome inhibitor, PS-
341 (bortezomib, Velcade®; Millenium Pharmaceuticals Inc.,
Cambridge, MA, USA and Johnson Pharmaceutical Research
and Development, LLC, Raritan, NJ, USA), is a dipeptide
boronic acid analog with the cell-death-inducing activity found
in several tumor cell lines and animal models [19-21]. The
mechanism of action of PS-341 has been shown to be inhibi-
tion of the β5-subunit and the β1-subunit, with the β5-subunit
as the predominant cell-death inducing target [22].
Because clinically available proteasome inhibitors are associ-
ated with some toxicity [13,14], natural proteasome inhibitors
with less or no toxicity are attractive potential anticancer
agents. The pursuit for nontoxic natural compounds has been
stimulated by our findings that apigenin potently inhibits the
chymotrypsin-like activity of a purified 20S proteasome and
26S proteasome in cultured tumor leukemia cells [6,9]. Pro-
teasome inhibition led to the accumulation of proteasome tar-
get proteins (such as IκBα and Bax) and to subsequent
induction of apoptosis in human leukemia cancer cells, as
measured by activation of caspases and cleavage of
poly(ADP-ribose) polymerase (PARP) [6,9].
The chemopreventive effects of apigenin are well defined [23],
and we have observed cytotoxic effects in leukemia cells [6,9].
Whether apigenin has potential antibreast cancer activity and
whether it could target the breast cancer proteasome, how-
ever, remain unclear. In the current study, we provide evidence
that the proteasome-inhibitory activity of apigenin extends to
breast cancer cells and tumors. Proteasome inhibition, growth
suppression, and apoptosis induction were observed in cul-
tured breast cancer MDA-MB-231 cells treated with apigenin.
Since our previous studies revealed that apigenin was innocu-
ous to normal cells [6,9], treatment of breast-cancer-bearing
nude mice with apigenin was examined – resulting in tumor
growth inhibition and massive apoptosis induction, associated
with proteasome inhibition in vivo. No apparent toxicity to the
tested animals was observed. The data suggest that apigenin
acts as a natural proteasome inhibitor under physiological con-
ditions. While cancer prevention has been the predominant
attribute assigned to apigenin, our findings are indicative of
great potential for cancer treatment.
Materials and methods
Materials
Apigenin, bisbenzimide Hoechst number 33258 stain, 3-[4,5-
dimethyltiazol-2-yl]-2.5-diphenyl-tetrazolium bromide (MTT),
dimethylsulfoxide (DMSO), cremophor and other chemicals
were purchased from Sigma-Aldrich (St Louis, MO, USA).
RPMI 1640, penicillin, and streptomycin were purchased from
Invitrogen (Carlsbad, CA, USA). The fluorogenic peptide sub-
strates Suc-LLVY-AMC (for the proteasomal chymotrypsin-like
activity) and N-acetyl-DEVD-AMC (for caspase-3/caspase-7
activity) were from Calbiochem (San Diego, CA, USA). Mouse
monoclonal antibody against human PARP was purchased
from BIOMOL International LP (Plymouth Meeting, PA, USA).
Mouse monoclonal antibodies against Bax (B-9), ubiquitin
(P4D1), goat polyclonal antibody against actin (C-11), rabbit
polyclonal antibody against IκBα (C15), and secondary anti-
bodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). The antibody of p27 for immunohistochemistry was
from Novocastra Laboratories Ltd (Newcastle upon Tyne, UK).
Cell culture and cell extract preparation
MDA-MB-231 cells were grown in RPMI 1640 supplemented
with 10% fetal bovine serum, 100 u/ml penicillin, and 100 μg/
ml streptomycin. Cells were grown at 37°C in a humidified
incubator with an atmosphere of 5% CO2. A whole-cell extract
was prepared as previously described [24]. Briefly, MDA-MB-
231 breast cancer cells were grown to 60–70% confluency,
and were treated with 25 μM, 50 μM, 75 μM, or 100 μM api-
genin or DMSO control (at a concentration equivalent to the
volume used for the highest concentration of apigenin or ≤
0.1%) for 24 hours. At the endpoint of the experiments, cells
were harvested, washed twice with PBS and homogenized in
a lysis buffer (50 mM Tris (pH 8.0), 5 mM ethylenediamine
tetraacetic acid, 150 mM NaCl, 0.5% NP40). After 30 minutes
of rocking at 4°C, the mixtures were centrifuged at 12,000 ×
g for 15 minutes and the supernatants were collected as
whole-cell extracts.
Proteasomal chymotrypsin-like and caspase-3/caspase-
7 activity assays
Whole-cell extracts (10 μg) of cells treated with apigenin or
tumor tissue extracts (10 μg) from human breast tumor
xenograft were incubated for 2.5 hours at 37°C in 100 μl
assay buffer (50 mmol/l Tris–HCl, pH 7.5) with 10 μmol/l fluor-
ogenic substrate Suc-LLVY-AMC (for proteasomal chymot-
rypsin-like activity) or Ac-DEVD-AMC (for caspase-3/caspase-
7 activity) as described previously [25]. After incubation, pro-
duction of free hydrolyzed 7-amino-4-methylcoumarin (AMC)
groups liberated by substrate hydrolysis was fluorometrically
measured using a Victor 3 Multilabel Counter with an excita-
tion filter of 380 nm and an emission filter of 460 nm (Perk-
inElmer, Boston, MA, USA).
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Cell viability/proliferation assay
The MTT assay, an index of cell viability and cell growth, was
used to determine the effects of various compounds on MDA-
MB-231 breast cancer cells. Cells were plated in a 96-well
plate and were grown to 70–80% confluence, followed by
addition of each compound at the indicated concentrations.
After 24 hours of incubation at 37°C, the cell viability/prolifer-
ation was measured as previously described [26]. All samples
were assayed in triplicate in three independent experiments,
and the mean value for each experiment was calculated. The
results are displayed as the mean ± standard deviation and are
expressed as percentage of the control, which was consid-
ered to be 100%.
Cellular morphology analysis
A Zeiss (Thornwood, NY, USA) Axiovert 25 microscope was
used for all microscopic imaging with either phase contrast for
cellular morphology, as previously described [27].
Western blot analysis
The whole-cell extracts or tumor lysates were separated by
SDS-PAGE gel and were transferred to a nitrocellulose mem-
brane. Western blot analysis was performed using specific
antibodies against ubiquitin, Bax, IκBα, PARP or β-actin, fol-
lowed by visualization using the enhanced chemilumines-
cence reagent, as previously described [27].
Human breast tumor xenograft experiments
Female athymic nude mice, age 5 weeks, were purchased
from Taconic Research Animal Services (Hudson, NY, USA)
and were housed in accordance with protocols approved by
the Institutional Laboratory Animal Care and Use Committee of
Wayne State University. Human breast cancer MDA-MB-231
cells (5 × 106) suspended in 0.1 ml serum-free RPMI 1640
were inoculated subcutaneously in both flanks of each mouse
(four mice per group).
When the tumors reached sizes of ~120 mm3 on average, the
mice were randomly grouped (n = 4) and were treated by daily
subcutaneously injection with 25 or 50 mg/kg apigenin, or
vehicle (10% DMSO, 40% Cremophor/ethanol (3:1) and
50% PBS). The tumor size was measured every other day
using calipers, and the tumor volumes were calculated accord-
ing to a standard formula: length × width2/2. Mice were sacri-
ficed after 29 days of treatment. The tumors were collected
and photographed and the tumor tissues were used for multi-
ple assays.
Terminal nucleotidyl transferase-mediated nick end 
labeling and immunohistochemistry using tumor tissue 
samples
The terminal nucleotidyl transferase-mediated nick end labe-
ling (TUNEL) assay using an in situ apoptosis detection kit,
and immunostaining of p27 were performed as described pre-
viously [27]. The proteasomal chymotrypsin-like activity assay
and western blot analysis using animal tumor samples were
performed as described above using cultured breast cancer
cells.
Statistical analysis
To evaluate the difference between a treatment and control,
the Student t test was applied. The level of significance was
set at P < 0.05.
Results
Apigenin could inhibit cell viability/proliferation and could acti-
vate caspase-3/caspase-7 activity of MDA-MB-231 breast
cancer cells in a dose-dependent manner. We previously
showed that leukemia Jurkat T cells exposed to increasing
concentrations of apigenin (up to 50 μM) were subject to up
to 80% cell death after 24 hours of treatment [6]. In the
present study, we first investigated the effects of apigenin
(Figure 1a) in a dose-dependent manner (25, 50, 75, or 100
μM) on the highly metastatic and invasive human breast can-
cer cell line, MDA-MB-231 cells. The results of an MTT assay
revealed that apigenin inhibited cell viability, and potentially
proliferation, after 24 hours of treatment in a dose-dependent
manner (Figure 1b). Compared with the DMSO control, treat-
ment with 25 μM, 50 μM, 75 μM and 100 μM apigenin inhib-
ited cell viability/proliferation by 12%, 27%, 42%, and 49%,
respectively (Figure 1b). Furthermore, dose-dependent cas-
pase-3/caspase-7 activation was observed in the same exper-
iment with a nearly five-fold increase in the cells treated at the
highest concentration (Figure 1c). Additionally, morphological
changes were observed after increasing doses of apigenin in
the same experiment (Figure 1d). Compared with the DMSO
control, cells became elongated, losing their characteristic
morphology and possibly indicating cellular stress (Figure 1d).
We have previously shown that apigenin can inhibit the chy-
motrypsin-like proteasome activity in leukemia Jurkat T cells
[6]. We therefore hypothesized that apigenin could likewise
target the tumor cellular proteasome in MDA-MB-231 cells. To
determine whether the reduced cell viability/proliferation by
apigenin was due to its proteasome-inhibitory activity, MDA-
MB-231 cells were treated with 25 μM, 50 μM, 75 μM, or 100
μM apigenin for 24 hours. After treatment, proteins were
extracted and were used to measure the proteasome inhibition
by the fluorogenic proteasomal chymotrypsin-like activity
assay and by western blot analysis. The proteasomal chymot-
rypsin-like activity was inhibited by 17%, 20%, 29%, and 40%
in the cells treated with 25 μM, 50 μM, 75 μM, and 100 μM
apigenin, respectively (Figure 2a). Western blot analysis
revealed an accumulation of ubiquitinated proteins (indicated
by the increased intensity of the protein smear compared with
the DMSO control) and the proteasome target protein Bax,
most predominantly in cells exposed to the highest concentra-
tions (Figure 2b). We have previously reported an ubiquiti-
nated form of IκBα protein with a molecular weight of about 56
kDa [9]. A similar p56 band appeared after treatment of
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apigenin at 50–100 μM, detectable by the specific antibody to
IκBα (Figure 2b, arrow).
Inhibition of the proteasomal chymotrypsin-like activity, but not
trypsin-like activity, has been shown to be associated with
apoptosis induction in cancer cells [11,12]. To investigate
whether the proteasomal inhibition is associated with apopto-
sis induction, the presence of cleaved PARP was examined.
Apoptosis-specific cleaved PARP was detected in cells
treated with 50 μM apigenin and higher concentrations (Fig-
ure 2b). These results demonstrate that apigenin is able to
inhibit the proteasomal chymotrypsin-like activity, resulting in
apoptosis induction in human breast cancer MDA-MB-231
cells.
Apigenin inhibits the growth of human breast cancer
xenografts, associated with proteasome inhibition and apopto-
sis induction in vivo. After we demonstrated that apigenin
could inhibit proteasomal activity and induce apoptosis in cul-
tured breast cancer cells (Figures 1 and 2), we then deter-
mined whether apigenin could exert antitumor activity and
whether that activity is associated with proteasome inhibition
and apoptosis induction. Breast cancer MDA-MB-231 cells (5
× 106) were implanted subcutaneously in 5-week-old female
Figure 1
Antiproliferative and apoptosis inductive activities of apigenin. (a) Chemical structure of apigenin. (b) Viability/proliferation-inhibitory effect of api-
genin on the MDA-MB-231 breast cancer cell line. MDA-MB-231 cells were treated for 24 hours with increasing concentrations of apigenin fol-
lowed by a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide assay. (c) Activation of caspase-3/caspase-7 activity in MDA-MB-231 cells 
treated with indicated concentrations of apigenin for 24 hours, followed by measuring the caspase-3/caspase-7 activity in cell extracts. (d) Examina-
tion for morphological changes visualized by phase-contrast imaging (100× magnification). Three independent experiments were performed and 
each individual experiment was tested in triplicate ((b) and (c)). Similar results were found with all experiments and the data shown represent one 
experiment; bars, standard deviation. DMSO, dimethylsulfoxide. *P < 0.05, **P < 0.01.
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athymic nude mice. Upon the tumors reaching a palpable size
(~120 mm3 on average), the mice were treated
subcutaneously with either the vehicle control or with 25 or 50
mg/kg apigenin daily. Significant tumor growth inhibition by
apigenin was observed after 29 days of treatment,
demonstrating that apigenin has antitumor activity (Figure 3a).
Control tumors grew to an average size of 1,077 ± 114 mm3,
while 25 mg/kg apigenin-treated tumors grew to 842 ± 71
mm3 and 50 mg/kg apigenin-treated tumors grew to 622 ± 66
mm3. This corresponds to 22% growth inhibition in the 25 mg/
kg apigenin-treated tumors (P < 0.05; Figure 3a) and to 43%
growth inhibition in the 50 mg/kg apigenin-treated tumors (P
< 0.01; Figure 3a). We monitored the body weight of mice
from each group, and the average body weight on the last day
of treatment was 26.8 g, 26.5 g and 26.3 g from the mice
treated with the solvent, with 25 mg/kg apigenin, or with 50
mg/kg apigenin, respectively. The data of the body weight sug-
gested that there was no toxicity of apigenin observed in the
treated mice.
At the end of the experiment, the MDA-MB-231 tumors were
collected and used for proteasome activity assays and for
western blot analysis. The proteasomal chymotrypsin-like
activity was inhibited by ~20% and ~50% in the tumors
treated with 25 mg/kg and 50 mg/kg apigenin, respectively,
compared with the control mice (Figure 3b). Consistently in
western blot analysis, the accumulation of IκBα protein and a
trend of increased Bax protein expression were observed in
tumors treated with apigenin, especially in the tumors treated
with 50 mg/kg apigenin (Figure 3c). In addition, the immuno-
histochemistry results confirmed the increased expression of
p27 only in the tumors treated with apigenin (Figure 3d). Api-
genin therefore appears able to inhibit tumor proteasome
activity and act as an antiproliferative agent in vivo.
To determine whether apoptosis is responsible for the
observed antitumor activity of apigenin, immunohistochemistry
of TUNEL was examined. The results revealed that an average
of 10 ± 1% and 17 ± 2% of apoptotic cells, indicated by
TUNEL positivity in four tumor slides of each group, were
observed in tumors from animals treated with 25 mg/kg and
50 mg/kg apigenin, respectively (Figure 3d). There were some
faint TUNEL-positive cells detected in the solvent-treated
tumors (Figure 3d), indicating that this background was
derived either from a solvent effect or from spontaneous tumor
cell apoptosis. Taken together, these data show that the ability
of apigenin to inhibit the proteasomal chymotrypsin-like activity
is probably responsible for the observed induction of apopto-
sis in breast tumors in vivo.
Discussion
Chemotherapy and radiotherapy have an important role as sin-
gle modalities for cancer treatment; however, they largely have
limited effectiveness in the treatment of solid human tumors
that often become drug resistant and are often accompanied
Figure 2
Apigenin-induced proteasomal inhibition and apoptosis in MDA-MB-231 breast cancer cells
231 breast cancer cells. (a) Inhibition of proteasomal chymotrypsin 
(CT)-like activity by apigenin in MDA-MB-231 cells. Cells were treated 
with various concentrations of apigenin for 24 hours, were harvested 
and were analyzed for the proteasomal chymotrypsin-like activity in cell 
extracts. (b) Western blot analysis for accumulation of ubiquitinated 
proteins (Ub-Prs), Bax, IκBα and poly(ADP-ribose) polymerase cleav-
age (PARP) in the above prepared cell extracts after 72 hours of treat-
ment. Arrow, ubiquitinated IκBα (p56). Three independent experiments 
were performed and each individual experiment was tested in triplicate. 
Similar results were found with all experiments and the data shown rep-
resent one experiment; bars, standard deviation. DMSO, dimethylsul-
foxide. *P < 0.05, **P < 0.01. The number under each band of the 
western blot indicates a quantitative analysis by densitometry. Quantita-
tive number for IκBα included both bands of intact IκBα (p37) and 
ubiquitinated IκBα (p56).
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by severe drug-related side effects [28]. In an attempt to
improve traditional therapies, the proteasome has become an
increasingly important molecular target.
The antitumor and chemosensitizing properties of the protea-
some inhibitor PS-341 are well documented [29]. Toxicity
from bortezomib, however, has sparked an interest for identify-
ing nontoxic natural proteasome inhibitors such as the
Figure 3
Apigenin antitumor activity associated with inhibition of proteasomal activity and induction of apoptosis in vivol ti it   i ti  f t i  i  vivo. Female nude mice bearing MDA-MB-
231 cell tumors were treated with the solvent control (Sol) or with 25 or 50 mg/kg/day apigenin (Api 25, Api 50) for 29 days. Tumors were collected 
after 29 days of treatment, and the prepared tissues were analyzed by multiple assays. (a) Inhibition of MDA-MB-231 tumor growth by apigenin. (b) 
Proteasomal chymotrypsin (CT)-like activity measured in the tumor samples. (c) Western blot analysis for accumulation of ubiquitinated proteins (Ub-
Prs), Bax, IκBα and actin presented three representative individual tumor samples from each group of mice. (d) Immunohistochemistry for p27 and 
terminal nucleotidyl transferase-mediated nick end labeling (TUNEL). Data points, mean tumor volume in each experimental group containing four 
mice; bars, standard deviation. *P < 0.05, **P < 0.01. Number under each band of the western blot indicates a quantitative analysis by densitometry 
compared with the loading control of actin.
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flavonoid apigenin that could potentially serve as nontoxic ther-
apeutic and chemopreventive strategies. A role for apigenin-
induced proteasome inhibition has been substantiated in our
previous work; apigenin and other flavonoids were shown to
have proteasome-inhibitory activity in human tumor cells, but
had little to no effect on normal, nontransformed cells [6,9].
We examined the effectiveness of apigenin in a breast cancer
model using human MDA-MB-231 cells. After 24 hours, api-
genin treatment inhibited breast cancer cell viability/prolifera-
tion by 50% with the highest concentration tested (Figure 1b).
We have previously shown that apigenin is able to inhibit the
chymotrypsin-like activity of a purified 20S proteasome [6].
We therefore hypothesized that the reduced cellular viability or
possibly reduced proliferation was due in large part to api-
genin's proteasomal inhibitory activity. To test this hypothesis,
MDA-MB-231 cells were treated for 24 hours with apigenin,
were harvested and lysed, and the cell extracts were examined
for their chymotrypsin-like activity and by western blot analysis.
At the highest concentration, proteasome activity was inhib-
ited by approximately 40% (Figure 2a) and accumulated levels
of ubiquitinated proteins, Bax and ubiquitinated IκBα were
observed (Figure 2b). It is likely that an extended treatment in
this in vitro model would provide even more striking data.
To ensure that the apparent proteasome inhibition by apigenin
treatment would lead to the induction of apoptosis, we exam-
ined the morphological changes, the event of activated cas-
pase-3/caspase-7 activity and, ultimately, the production of
the cleaved PARP fragment. MDA-MB-231 cells exposed to
apigenin exhibited changes in cellular morphology that may
indicate a cellular stress (Figure 1d). A true measure of apop-
tosis in apigenin-treated cells was observed by caspase-3/
caspase-7 activation and cleaved PARP most noticeably after
treatment with the highest concentration of apigenin (Figures
1c and 2b). Again, extended treatments may be warranted for
these apoptotic studies as well.
Because the in vitro findings in this epithelial cancer model
were so promising, we then examined the effects of apigenin
treatment in a mouse model. Apigenin has been shown to have
growth-inhibitory effects associated with cell-cycle regulation
in nude mice bearing prostate cancer tumors [30,31]. In our
current study, treatment with apigenin resulted in significant
inhibition of proteasomal chymotrypsin-like activity, accumula-
tion of proteasome target proteins (that is, Bax), and induction
of apoptosis in tumors (Figure 3). Associated with the
observed proteasome inhibition and apoptosis induction, sig-
nificant tumor growth inhibition (~43%) by apigenin at the
highest concentration was observed in this breast tumor
model (Figure 3a).
In the present work we have shown that apigenin, at relatively
high doses, exhibits no gross toxicity in an animal model while
exerting proteasome-inhibitory and growth-inhibitory effects
both in vitro and in vivo. This finding is of particular importance
for future studies, which may include the delivery of apigenin
in combination with other natural compounds or as a sensitiz-
ing agent to traditional cancer therapeutics. In fact, a recent
study suggested that apigenin may sensitize leukemia cells,
prostate cancer cells, and colon cancer cells by inducing the
expression of death receptor 5, which, in combination with
exogenous tumor necrosis factor-related apoptosis-inducing
ligand, acts synergistically to induce apoptosis while having no
effect on normal cells [32]. The evidence from these studies
suggests that apigenin has great potential to be further devel-
oped as a cancer therapeutic.
The concentrations of apigenin used to treat cultured breast
cancer cells and used in the animal model are most probably
higher than those found in the blood of individuals consuming
dietary apigenin. The dose for apigenin in this mouse model,
however, appeared to be well tolerated. During the 29-day
treatment, there was no overall gross toxicity observed. More
detailed microscopic and macroscopic pathologic studies are
required to definitively document the lack of toxicity when api-
genin is used at these concentrations.
Conclusion
The importance of the proteasome in the pathological state of
cancer and the potential for apigenin and other flavonoids as
natural inhibitors of the proteasome may provide a viable
modality for the prevention and treatment of some cancers.
The findings reported in the present article indicate that api-
genin appears to be a promising, novel anticancer agent, and
one of its mechanisms of action involves targeting the tumor
cellular proteasome and inducing apoptotic cell death. Using
an innocuous natural product or its prodrug as a chemosensi-
tizer may reduce the toxicity and boost the effectiveness of
current chemotherapeutics. Future analysis of apigenin in a
combinational regimen may elucidate increased effectiveness
of this novel agent in additional cancer models.
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